이상지질혈증의 국내 및 국외 치료 가이드라인 비교
Current Guidelines on the Management of Dyslipidemia
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Dyslipidemia is recognized as a prominent risk factor for cardiovascular and cerebrovascular diseases but it ismanageable through therapeutic and lifestyle intervention. Interpreting the latest guidelines is essential for an application ofrecommendation from guidelines into clinical practice. Therefore, this study aimed to compare the most recent guidelines ondyslipidemia treatment recommendations in Korea and USA. Methods: This study analyzed and compared 2015 Korean guidelinesfor the management of dyslipidemia, 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and2016 supportive guidelines from ACC. Results: A comparison was made focused on the following: target patients based oncardiovascular risk assessment, target goal, and treatment strategies including statin and non-statin therapies. Four target patientgroups by risk were suggested in 2015 Korean guideline and cardiovascular risk factors were also considered for initiation of lipidlowering therapy. Titrated statin regimen was recommended by Korean guideline to reach LDL cholesterol and non-HDLcholesterol target level. In 2013 ACC/AHA guideline, four statin benefit group was introduced considering ASCVD risk and highintensity statin or intermediate intensity statin use were recommended without dose titration. 2016 update was to support nonstatintherapy based on updated evidence and new consideration of ezetimibe, PCSK9-inhibitor and bile acid sequestrant wasbrought up. Conclusion: Guidelines are continuously updating as new and important clinical data are constantly released alongwith the advent of newly approved drugs for lipid disorder. This article provides resources that facilitates uptake of theserecommendations into clinical practice.
Abstract
Objective: Dyslipidemia is recognized as a prominent risk factor for cardiovascular and cerebrovascular diseases but it ismanageable through therapeutic and lifestyle intervention. Interpreting the latest guidelines is essential for an application ofrecommendation from guidelines into clinical practice. Therefore, this study aimed to compare the most recent guidelines ondyslipidemia treatment recommendations in Korea and USA. Methods: This study analyzed and compared 2015 Korean guidelinesfor the management of dyslipidemia, 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and2016 supportive guidelines from ACC. Results: A comparison was made focused on the following: target patients based oncardiovascular risk assessment, target goal, and treatment strategies including statin and non-statin therapies. Four target patientgroups by risk were suggested in 2015 Korean guideline and cardiovascular risk factors were also considered for initiation of lipidlowering therapy. Titrated statin regimen was recommended by Korean guideline to reach LDL cholesterol and non-HDLcholesterol target level. In 2013 ACC/AHA guideline, four statin benefit group was introduced considering ASCVD risk and highintensity statin or intermediate intensity statin use were recommended without dose titration. 2016 update was to support nonstatintherapy based on updated evidence and new consideration of ezetimibe, PCSK9-inhibitor and bile acid sequestrant wasbrought up. Conclusion: Guidelines are continuously updating as new and important clinical data are constantly released alongwith the advent of newly approved drugs for lipid disorder. This article provides resources that facilitates uptake of theserecommendations into clinical practice.
참고문헌 (18)
- Benjamin EJ, "Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association", Circulation, 135(10), pp.e146~e603 (2017)
- "Korea Health Statistics 2015. Korea National Health and Nutrition Examination Survey (KNHANES VI-3)"[URL]
- 김현창, "한국인 이상지질혈증의 역학", 대한의사협회지, 59(5), pp.352~357 (2016), 대한의사협회[DOI]
- "The National Health Plan 2020" (2011)[URL]
- Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
- Stone NJ, "American College of Cardiology", American Heart Association Task Force on Practice Guidelines. 2013 ACC, American Heart Association Task Force on Practice Guidelines, pp.Circulation, 2014[DOI]
- Lloyd-Jones DM, "2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents", J Am Coll Cardiol, 68, pp.92~125 (2016)
- Goff DC, "2013 ACC", AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults., "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report", Circulation, 106, pp.3143~3421 (2002)
- Lloyd-Jones DM, "2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways", J Am Coll Cardiol (2017)
- AIM-HIGH Investigators, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)
- Koren MJ, "Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study", J Am Coll Cardiol, 44, pp.1772~1779 (2004)
- Carreras ET, "Dyslipidemia : Current Therapies and Guidelines for Treatment", US Cardiology Review, 11(1), pp.10~15 (2017)
- Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Gencer B, "PCSK9 inhibitors", Swiss Med Wkly, 145, pp.w14094~ (2015)
- Sabatine MS, "FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease", N Engl J Med, 376, pp.1713~1722 (2017)
- Ridker PM, "SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients", N Engl J Med, 376, pp.1527~1539 (2017)